single10MG
FOXO4-DRI
10MG Protocol
FOXO4-DRI 10MG
Injection Freq.
Inject once daily
Cycle Sched.
8–16 weeks; longer cycles may use intermittent dosing schedules as tolerated
Reconstitution
3.0 mL BAC water
Promotes selective clearance of senescent cells in animal studies
Improvements in tissue regeneration and organ function reported after senescent-cell clearance
Reduced inflammation markers described in preclinical studies
Stability advantages attributed to D-retro-inverso design
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 250 mcg | 7.5 |
| 2 | Weeks 5–8 | 375 mcg | 11 |
| 3 | Weeks 9–12 | 500 mcg | 15 |
| 4 | Weeks 13–16 | 500 mcg | 15 |
Inject once daily
8–16 weeks; longer cycles may use intermittent dosing schedules as tolerated
FOXO4-DRI is presented as an investigational senolytic strategy rather than a conventional hormone-like peptide. The protocol describes it as a D-retro-inverso peptide engineered for stability and resistance to enzymatic breakdown. Its proposed mechanism is disruption of the FOXO4–p53 protein interaction. In senescent cells, FOXO4 is described as helping sequester p53 in the nucleus; when FOXO4-DRI blocks this interaction, p53 relocates to mitochondria and triggers apoptosis selectively in senescent (aged/dysfunctional) cells while sparing healthy cells. The page summarizes animal data suggesting reduced senescent-cell burden and downstream improvements in tissue function and age-related pathology markers after treatment, with additional reports of improved inflammatory markers and certain endocrine measures in aged models. A key limitation highlighted is that human clinical safety and efficacy data are not yet available; therefore, tolerability is extrapolated and injection-site irritation is listed as a possible local effect.
No human clinical safety/efficacy data available (per page)
Possible injection-site reactions (mild redness/irritation)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)